scispace - formally typeset
Y

Ysamar Barrios

Researcher at Hospital Universitario de Canarias

Publications -  25
Citations -  700

Ysamar Barrios is an academic researcher from Hospital Universitario de Canarias. The author has contributed to research in topics: Population & Calcitriol receptor. The author has an hindex of 14, co-authored 25 publications receiving 661 citations. Previous affiliations of Ysamar Barrios include University of La Laguna.

Papers
More filters
Journal ArticleDOI

Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis

TL;DR: The novel findings of this study on patients with severe sepsis are that reduced MMP-9/TIMP-1 ratios and increased M MP-10 levels may be of great pathophysiologic significance in terms of severity and mortality, and that TIMP- 1 levels may represent a biomarker to predict the clinical outcome of patients with sepsi.
Journal ArticleDOI

Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation

TL;DR: Therapy with low-dose calcium supplements during 1 year, plus intermittent calcitriol for 3 months after RT, is safe, decreases PTH levels more rapidly, and prevents bone loss at the proximal femur; a more pronounced effect is seen in recipients with at least one at-risk allele of the VDR genotype.
Journal ArticleDOI

Vitamin D receptor gene polymorphisms, bone mass, bone loss and prevalence of vertebral fracture: differences in postmenopausal women and men.

TL;DR: VDR gene polymorphisms are related to bone mass and bone loss in women and a trend in the prevalence of vertebral fractures was observed in postmenopausal women but not in men.
Journal ArticleDOI

Factors associated with excessive bleeding in cardiopulmonary bypass patients: a nested case-control study.

TL;DR: Excessive postoperative bleeding in CPB patients was associated with demographics, particularly less pronounced BMI, and surgical factors together with serine protease activation, including 5G homozygotes for PAI-1.